SCYNEXIS Stock

SCYNEXIS Capital Intensity

The Capital Intensity Ratio of SCYNEXIS (SCYX) as of Aug 7, 2026 is 2,419.73 %. In the previous year, Capital Intensity Ratio was 91.63 % — a change of 2,540.74% (higher).

Capital Intensity

2,419.73 %

YoY

2,540.74%

Last updated:

Capital Intensity Ratio of SCYNEXIS is 2026 2,419.73 % . Capital Intensity Ratio of SCYNEXIS was 2025 91.63 % . It decreases by 2,540.74% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Capital Intensity Ratio of SCYNEXIS is 2,419.73 % in 2026.

Capital Intensity Ratio of SCYNEXIS changed from 91.63 % to 2,419.73 %, representing a 2,540.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

Profitability — SCYNEXIS

All Key Metrics — SCYNEXIS